Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 11:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 201 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Efavirenz Clear all
Completed Phase 4 Interventional Results available

Effects of Switching Efavirenz to Raltegravir on Vascular Function and Bone Markers in HIV-infected Patients

NCT01270802
View directory record Official record
Conditions
HIV
Interventions
Tenofovir/emtricitabine, Tenofovir/emtricitabine/efavirenz, Raltegravir
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Oct 17, 2026, 11:20 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

NCT00042289
View directory record Official record
Conditions
HIV Infections
Interventions
atazanavir/cobicistat, darunavir/ritonavir dosage #1, darunavir/ritonavir dosage #2, darunavir/ritonavir dosage #3, elvitegravir/cobicistat, dolutegravir, tenofovir alafenamide fumarate (TAF), TAF w/cobicistat, TAF w/cobicistat or ritonavir, efavirenz, darunavir/cobicistat, lopinavir/ritonavir dosage #1, atazanavir/ritonavir/tenofovir dosage #1, rifampicin, ethambutol, isoniazid, pyrazinamide, kanamycin, amikacin, capreomycin, moxifloxacin, levoflaxacin, ofloxacin, ethionamide/prothionamide, terizidone/cycloserine, para-aminosalicylic acid (PAS), high dose INH, bedaquiline, clofazamine, delamanid, linezolid, pretomanid, ethinyl estradiol, etonogestrel implant, nevirapine, amprenavir, abacavir, lopinavir/ritonavir dosage #2, indinavir/ritonavir dosage #1, fosamprenavir/ritonavir, lopinavir/ritonavir dosage #3, atazanavir/ritonavir dosage #1, didanosine delayed release (Videx® EC), emtricitabine, tenofovir, nelfinavir dosage #1, tipranavir/ritonavir, lopinavir/ritonavir dosage #4, raltegravir, etravirine, maraviroc, atazanavir/ritonavir dosage #2, tenofovir/atazanavir/ritonavir dosage #2, nelfinavir dosage #2, indinavir/ritonavir dosage #2, rilpivirine, darunavir/ritonavir dosage #4
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
1,578 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2020
U.S. locations
39
States / cities
Birmingham, Alabama • La Jolla, California • Long Beach, California + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Oct 17, 2026, 11:20 PM EDT
Completed Phase 1 Interventional

Effects of Anti-HIV Drugs on the Hepatitis C Virus (HCV) in Adults Infected With Both HCV and HIV

NCT00545558
View directory record Official record
Conditions
Hepatitis C, HIV Infections
Interventions
Efavirenz, Emtricitabine/Tenofovir disoproxil fumarate
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
2
States / cities
Cincinnati, Ohio • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 12, 2014 · Synced Oct 17, 2026, 11:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Effect of Efavirenz on the Plasma Levels of Nemtabrutinib (MK-1026-014)

NCT06698016
View directory record Official record
Conditions
Healthy
Interventions
Nemtabrutinib, Efavirenz
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Oct 17, 2026, 11:20 PM EDT
Completed Not applicable Interventional

DART I - A Phase IV Study of 3 Antiretroviral Medicines in Combination, in HIV Patients Who Have Not Been Previously Treated With Antiretroviral Therapy

NCT00116415
View directory record Official record
Conditions
HIV Infections, AIDS
Interventions
efavirenz; didanosine EC; lamivudine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
9
States / cities
Washington D.C., District of Columbia • Orlando, Florida • Columbus, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2011 · Synced Oct 17, 2026, 11:20 PM EDT
Completed Phase 1 Interventional Results available

Evaluating the Safety and Pharmacokinetics of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection

NCT02778204
View directory record Official record
Conditions
HIV Infections
Interventions
Maraviroc
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 3 Days
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
5
States / cities
Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2022 · Synced Oct 17, 2026, 11:20 PM EDT
Terminated No phase listed Observational

Antiretroviral Localization in Gut-Associated Lymphoid Tissue and Lower Female Genital Tract Tissue of HIV+ Subjects

NCT02641444
View directory record Official record
Conditions
HIV
Interventions
Blood plasma collection, Cervical and Vaginal Biopsy, Colonoscopy with Ileal and Rectal Biopsy
Procedure
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Oct 17, 2026, 11:20 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Clinical Trial of CNS-targeted HAART (CIT2)

NCT00624195
View directory record Official record
Conditions
HIV Infections
Interventions
FDA Approved Antiretroviral Therapy (see list below)
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
5
States / cities
San Diego, California • San Francisco, California • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2014 · Synced Oct 17, 2026, 11:20 PM EDT
Completed Not applicable Interventional

A Study to Evaluate Various Combinations of Anti-HIV Medications to Treat Early HIV Infection

NCT00000919
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Lamivudine/Zidovudine, Ritonavir, Hydroxyurea, Abacavir sulfate, Amprenavir, Nelfinavir mesylate, Efavirenz, Lamivudine, Stavudine, Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2002
U.S. locations
63
States / cities
Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2012 · Synced Oct 17, 2026, 11:20 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients

NCT01495702
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, HIV Infections
Interventions
NNRTI, FTC/TDF, Stribild
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
439 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
39
States / cities
Phoenix, Arizona • Beverly Hills, California • Hayward, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2016 · Synced Oct 17, 2026, 11:20 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of CYP2B6 Genetic Polymorphisms on Efavirenz Pharmacokinetics

NCT00668395
View directory record Official record
Conditions
HIV
Interventions
Efavirenz
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 49 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 26, 2014 · Synced Oct 17, 2026, 11:20 PM EDT
Completed Not applicable Interventional Results available

Advanced Neuroimaging Evaluation of CNS Changes Associated With Efavirenz Therapy Switch to an Raltegravir-based Regimen

NCT01978743
View directory record Official record
Conditions
HIV, HIV-associated Neurocognitive Disorder, Neurotoxicity
Interventions
Raltegravir
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 26, 2017 · Synced Oct 17, 2026, 11:20 PM EDT
Completed Phase 1 Interventional

Antiretroviral Drug Interaction Study in Volunteers With HIV

NCT01479361
View directory record Official record
Conditions
HIV, PCP, Toxoplasmosis
Interventions
Atovaquone 750 mg twice daily, Atovaquone 1500 mg twice daily
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 70 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Oct 17, 2026, 11:20 PM EDT
Completed Phase 3 Interventional Results available

Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC

NCT02469246
View directory record Official record
Conditions
HIV-1 Infection
Interventions
F/TAF, ABC/3TC, ABC/3TC Placebo, F/TAF Placebo, 3rd ARV agent
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
567 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
34
States / cities
Phoenix, Arizona • Beverly Hills, California • La Jolla, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2019 · Synced Oct 17, 2026, 11:20 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children

NCT00039741
View directory record Official record
Conditions
HIV Infections
Interventions
NRTIs (ABC, FTC, FTC/TDF, 3TC, 3TC/AZT, d4T, TDF, ddC, AZT), NNRTIs (EFV, NVP), PIs (AMP, IDV, LPV/r, NFV, SQV, RTV)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
30 Days to 18 Years
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
29
States / cities
Alhambra, California • Long Beach, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 17, 2026, 11:20 PM EDT
Completed Not applicable Interventional Results available

Pilot Study on the Effect of Adding Raltegravir +/- a Second Drug on HIV Levels in the Gut

NCT00884793
View directory record Official record
Conditions
HIV Infections
Interventions
raltegravir, Study NNRTI, Study PI
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 23, 2012 · Synced Oct 17, 2026, 11:20 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants

NCT03631732
View directory record Official record
Conditions
HIV-1 Infection
Interventions
B/F/TAF, NRTIs, Third Agent
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
82
States / cities
Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 53 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Oct 17, 2026, 11:20 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen

NCT05502341
View directory record Official record
Conditions
HIV-1-infection
Interventions
Bictegravir, Lenacapavir, BIC/LEN FDC, Stable Baseline Regimen
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
689 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
40
States / cities
Berkeley, California • Beverly Hills, California • Los Angeles, California + 34 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 17, 2026, 11:20 PM EDT
Completed Not applicable Interventional Results available

Pilot Study of Raltegravir/Truvada Versus Efavirenz/Truvada for Adults With Acute IV-1 Infection

NCT00734344
View directory record Official record
Conditions
Acute HIV Infection
Interventions
Raltegravir, Efavirenz, Emtricitibine, Tenofovir disoproxil once daily, Tenofovir disoproxil twice daily
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 30, 2016 · Synced Oct 17, 2026, 11:20 PM EDT
Completed Phase 3 Interventional

Rollover Study for Zerit (Stavudine) ER Studies (-096, -099)

NCT00116298
View directory record Official record
Conditions
HIV Infections, AIDS
Interventions
stavudine, efavirenz, lamivudine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
Not listed
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
19
States / cities
Berkeley, California • Los Angeles, California • West Hollywood, California + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2011 · Synced Oct 17, 2026, 11:20 PM EDT
Completed Phase 2 Interventional

Effectiveness of ABT-378/Ritonavir Plus Lamivudine Plus Efavirenz Plus Tenofovir DF in HIV-Infected Patients

NCT00038220
View directory record Official record
Conditions
HIV Infections
Interventions
Lopinavir/ritonavir, Efavirenz, Lamivudine, Tenofovir DF
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 27, 2006 · Synced Oct 17, 2026, 11:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction - Oral Contraceptive

NCT00399685
View directory record Official record
Conditions
HIV Infections
Interventions
Ortho Tri-Cyclen LO, Ortho Cyclen, Ortho Cyclen + Efavirenz
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
2
States / cities
San Diego, California • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Apr 14, 2011 · Synced Oct 17, 2026, 11:20 PM EDT
Completed Phase 1 Interventional

Combination Drug Treatment of Pediatric HIV Infection

NCT00001818
View directory record Official record
Conditions
HIV Infection
Interventions
Hydroxyurea
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 17, 2026, 11:20 PM EDT
Completed Phase 3 Interventional

Comparing the Safety, Effectiveness, and Tolerability of Three Anti-HIV Drug Regimens for Treatment-Naive Patients

NCT00050895
View directory record Official record
Conditions
HIV Infections
Interventions
Lopinavir/ritonavir, Efavirenz, Stavudine, Zidovudine, Lamivudine, Tenofovir disoproxil fumarate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
775 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
59
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 34 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 17, 2026, 11:20 PM EDT